Portal de Periódicos da CAPES

Presenilins, Alzheimer's Disease, and Capacitative Calcium Entry

2000; Cell Press; Volume: 27; Issue: 3 Linguagem: Inglês

10.1016/s0896-6273(00)00048-9

1097-4199

James W. Putney,

Computational Drug Discovery Methods

Currently about 20 million people suffer from the debilitating age-related dementia known as Alzheimer's disease (4Haass C. De Strooper B Science. 1999; 286: 916-919Crossref PubMed Scopus (357) Google Scholar). Although only a minority of cases involve the familial form of the disease, clues to the molecular basis of Alzheimer's disease in the more prevalent sporadic form have been obtained from knowledge of the mutant genes and especially the structures and functions of the proteins they encode (1Annaert W. De Strooper B Trends Neurosci. 2000; 22: 439-443Abstract Full Text Full Text PDF Scopus (117) Google Scholar). A major cause of the familial form of Alzheimer's disease is a missense mutation in one of three genes coding for amyloid precursor protein (APP), presenilin 1 (PS1), or presenilin 2 (PS2). The relationship between altered APP function and Alzheimer's disease is reasonably well established. APP is the precursor for amyloid peptides that are produced by the action of α-, β-, and γ-secretases. The cleavage of partially processed APP (the β-secretase product) by γ-secretase normally yields a 40 amino acid peptide termed Aβ. However, all missense mutations in APP, as well as in the presenilins, results in cleavage at a site two amino acids downstream yielding a 42 amino acid product, Aβ1-42, or Aβ42. This slightly longer peptide is apparently much more adhesive than Aβ and is a major component of the amyloid plaques found deposited in the brains of patients who have died from Alzheimer's disease. Certain missense mutations in the presenilins are also associated with the Alzheimer's phenotype, and when transfected into cells, result in production of Aβ42. Knockouts of presenilins do not produce this phenotype, leading to the conclusion that familial Alzheimer's disease mutations result in a toxic gain of function. Although not originally predicted form their structure, presenilins now appear to have protease activity, and recent studies have provided strong evidence that presenilin 1 (and likely presenilin 2) is the γ-secretase responsible for formation of Aβ and Aβ42 (12Vassar R. Citron M Neuron. 2000; 27 (this issue,): 419-422Abstract Full Text Full Text PDF PubMed Scopus (258) Google Scholar, this issue of Neuron). In addition to direct effects on Aβ formation, presenilins are known to have effects on cellular Ca2+ metabolism (9Mattson M.P. LaFerla F.M. Chan S.L. Leissring M.A. Shepel P.N. Geiger J.D Trends Neurosci. 2000; 23: 222-229Abstract Full Text Full Text PDF PubMed Scopus (409) Google Scholar). In a report appearing in this issue of Neuron, Yoo et al. (13Yoo A.S. Cheng I. Chung S. Grenfell T.Z. Lee H. Pack-Chung E. Handler M. Shen J. Xia W. Tesco G. et al.Neuron. 2000; 27 (this issue,): 561-572Abstract Full Text Full Text PDF PubMed Scopus (264) Google Scholar) provide evidence that aberrant presenilin regulation of APP processing involves alterations in a specific calcium influx pathway, known as "capacitative calcium entry." A key component of the phospholipase C–inositol trisphosphate signaling pathway, capacitative calcium entry, has received most attention as the primary mode of regulated calcium entry in nonexcitable cells (10Putney Jr., J.W. Capacitative Calcium Entry. Landes Biomedical Publishing, Austin, TX1997Crossref Google Scholar). Recent findings establish that this pathway is active in neurons as well (3Bouron A FEBS Lett. 2000; 470: 269-272Abstract Full Text Full Text PDF PubMed Scopus (52) Google Scholar). When phospholipase C is activated through appropriate receptor pathways, inositol 1,4,5-trisphosphate (IP3) is liberated and binds to specific receptors/ion channels in the endoplasmic reticulum, causing the discharge of stored calcium to the cytoplasm. The resulting decline in calcium within the endoplasmic reticulum signals activation of plasma membrane calcium channels, a process that has been termed capacitative calcium entry. Much of the recent research on this pathway has focused on understanding the nature of the signal from the endoplasmic reticulum to the plasma membrane channels. There is considerable evidence indicating that activation of plasma membrane capacitative calcium entry channels depends on interaction with IP3 receptors in closely juxtaposed endoplasmic reticulum (7Kiselyov K. Xu X. Mozhayeva G. Kuo T. Pessah I. Mignery G. Zhu X. Birnbaumer L. Muallem S Nature. 1998; 396: 478-482Crossref PubMed Scopus (548) Google Scholar). This mode of signaling involving direct interaction of endoplasmic reticulum proteins with plasma membrane calcium channels has been termed "conformational coupling" (5Irvine R.F FEBS Lett. 1990; 263: 5-9Crossref PubMed Scopus (571) Google Scholar, 2Berridge M.J Biochem. J. 1995; 312: 1-11Crossref PubMed Scopus (1039) Google Scholar). This mechanism is distinct from the alternatively proposed mechanism of communication between the endoplasmic reticulum and plasma membrane, involving a putative diffusible messenger (11Randriamampita C. Tsien R.Y Nature. 1993; 364: 809-814Crossref PubMed Scopus (777) Google Scholar). How is capacitative calcium entry involved in the actions of normal and mutated presenilins? Yoo et al. (13Yoo A.S. Cheng I. Chung S. Grenfell T.Z. Lee H. Pack-Chung E. Handler M. Shen J. Xia W. Tesco G. et al.Neuron. 2000; 27 (this issue,): 561-572Abstract Full Text Full Text PDF PubMed Scopus (264) Google Scholar) noted that a number of studies had demonstrated alterations in cellular Ca2+ metabolism associated with Alzheimer's disease and, specifically, effects on the phospholipase C/IP3 pathway, including potentiation of IP3-mediated intracellular release of Ca2+ (6Ito E. Oka K. Etcheberrigaray R. Nelson T.J. McPhie D.L. Tofel-Grehl B. Gibson G.E. Aldon D.L Proc. Nat. Acad. Sci. USA. 1994; 91: 534-538Crossref PubMed Scopus (278) Google Scholar). Yoo et al. investigated the role of presenilins in a common and key component of this pathway, capacitative calcium entry. To examine effects on capacitative calcium entry, primary cortical neurons were incubated in calcium-free media containing an ER calcium-depleting reagent, washed and replenished with calcium-containing media. Resulting changes in capacitative calcium entry were monitored by imaging with the calcium-sensitive dye FURA-2. Transfection of cortical neurons with familial Alzheimer's disease-associated mutations of presenilin 1 resulted in a decrease in capacitative calcium entry. However, when presenilin 1 function was abrogated, by either a knockout or dominant-negative strategy, capacitative calcium entry was markedly potentiated. These results suggest that the normal PS1 protein may play a negative, modulatory role in the capacitative calcium entry pathway. Thus, in the disease state, missense mutations result in a gain-of-function effect and an increased inhibition of capacitative calcium entry. A key question is whether the alteration in capacitative calcium entry is an early, causative element in the disease pathway or, rather, a late and perhaps unrelated downstream event. To address this issue, Yoo et al. designed strategies to determine the relationship of capacitative calcium entry to the expression of the toxic peptide, Aβ42. Inhibition of capacitative calcium entry with the drug SKF96365 mimicked the effects of presenilin 1 mutations in inducing an increase in synthesis of Aβ42. However, SKF96365 did not induce an increase in Aβ42 in cells expressing a dominant-negative PS1. Interestingly, the degree of inhibition of capacitative calcium entry by SKF96365 was also attenuated in the PS1 dominant-negative-expressing cells, suggesting that the mechanism of action of this inhibitor may be more complex than originally suspected. Finally, induction of elevated Aβ42 levels by overproduction of APP, or direct addition of Aβ42 to cells did not affect capacitative calcium entry. Thus, the alteration in capacitative calcium entry appears capable of modulating Aβ42 levels, but not vice versa, suggesting that capacitative calcium entry is likely to occur upstream of Aβ42 cleavage. The aggregate observations presented in the study of Yoo et al. suggest that one cellular function of presenilins is regulation of capacitative calcium entry. When this regulation is modified by specific, Alzheimer's-associated missense mutations, this triggers a key biochemical component of the disease, increased formation of toxic Aβ42. How might such alterations in capacitative calcium entry produce this specific biochemical phenotype? One prediction, suggested by Yoo et al., is that the combined downregulated capacitative calcium entry and enhanced IP3-mediated release of Ca2+ associated with the disease mutations would result in diminished storage of Ca2+ in the endoplasmic reticulum. Alterations in endoplasmic reticulum Ca2+ homeostasis can have subtle or profound effects on protein expression or processing, and such alterations have been suggested to occur in a variety of neurodegenerative disorders, including Alzheimer's disease (9Mattson M.P. LaFerla F.M. Chan S.L. Leissring M.A. Shepel P.N. Geiger J.D Trends Neurosci. 2000; 23: 222-229Abstract Full Text Full Text PDF PubMed Scopus (409) Google Scholar). However, no experimental evidence for diminished Ca2+ storage was provided in the study by Yoo et al. In a recent report, Leissring et al. (8Leissring M.A. Akbari Y. Fanger C.M. Cahalan M.D. Mattson M.P. LaFerla F.M J. Cell Biol. 2000; 149: 793-797Crossref PubMed Scopus (275) Google Scholar) examined similar issues and also observed an inhibition of capacitative calcium entry in cells from transgenic mice expressing the Alzheimer's-associated mutant presenilin 1. In addition, they observed, as others have before, an augmented release of Ca2+ in response to cellular increases in IP3. Liessring et al. also examined the size of Ca2+ stores in the cells and, in contrast to the hypothesis presented by Yoo et al., found that Ca2+ stores were increased in PS1 mutant cells compared to controls. This increase in stored Ca2+ can nicely explain both the effect on IP3-mediated Ca2+ release and the effect on capacitative calcium entry (8Leissring M.A. Akbari Y. Fanger C.M. Cahalan M.D. Mattson M.P. LaFerla F.M J. Cell Biol. 2000; 149: 793-797Crossref PubMed Scopus (275) Google Scholar). IP3 would produce larger intracellular Ca2+ signals by virtue of a greater driving force for Ca2+ release, and capacitative calcium entry would be reduced since it depends on the level of Ca2+ remaining in the endoplasmic reticulum after discharge. In support of this interpretation, Leissring et al. found that if endoplasmic reticulum stores were completely discharged with the endoplasmic reticulum calcium ATPase inhibitor, thapsigargin, then no change in capacitative calcium entry was seen in cells from the transgenic, presenilin 1 mutant knockin mice. Yoo et al. point out the potential for pharmacological intervention, by using agonists for the capacitative calcium entry channels, in either treatment or prevention of Alzheimer's disease. However, the choice of therapeutic approach will depend on the resolution of the mechanisms underlying regulation of entry, as well as the effects on endoplasmic reticulum stores. If the hypothesis of Yoo et al. is correct, then we must seek to understand how presenilins can interact with the capacitative calcium entry signaling pathway and search for a means to overcome this inhibition. But in the context of the findings of Leissring et al. (8Leissring M.A. Akbari Y. Fanger C.M. Cahalan M.D. Mattson M.P. LaFerla F.M J. Cell Biol. 2000; 149: 793-797Crossref PubMed Scopus (275) Google Scholar), the issue may not be capacitative calcium entry signaling per se, but rather alterations in the basic cell biology of the endoplasmic reticulum and the regulation of its calcium storing capacity. Other possibilities may become apparent as continued work more precisely delineates the roles of endoplasmic reticulum calcium and capacitative calcium entry in the pathology of the disease. As is so often the case, not only do we have new cellular and molecular insights into the underlying causes of an important disease, but we may also have new clues to the signaling and regulatory mechanisms that control this prevalent and biologically significant calcium signaling pathway.